Outcome of acute myeloid leukaemia in Nigeria: clinician’s perspective

• DOI: 10.3332/ecancer.2021.1239
• Publication Date: 2021-05-25T09:42:12Z
• Authors: Ann Abiola Ogbenna; Olufemi Abiola Oy...; Christiana Oluwak...; Babajide Ayodeji ...; Obadiah Dapus Dam...; Esere Bernice Akp...; Gbenga Olorunfemi; Kehinde Adekola
• Keywords: Induction chemotherapy; Immunophenotyping

The outcome of acute myeloid leukaemia (AML) has remained a major concern even in developed countries.In resource poor countries, it is envisaged that the will be far worse because late presentations, lack appropriate diagnostic facilities and supportive care.However, data to validate this lacking many these countries an effective cancer registry.This study determined clinician's perspective care AML patients Nigeria their attitudes patients.Structured self-administered questionnaire was used assess perception outcomes care, contributory factors attitude patients.Ninetyeight percent clinicians reported suboptimal; 73.3% 90.6% having less than 31% surviving induction post-induction therapies, respectively.Sixty-six-point one (66.1%), 50% 62.7% have never immunophenotyping, cytogenetic or molecular studies, respectively, management under care.Access blood components other Red cells low; 23.3% had access apheresis platelets 55% fresh frozen plasma.Forty-six either give half dose chemotherapy offer only care.This early death rate three times higher with 9% likely survive first year compared about 32.9% Ontario.Approximately 28 units pooled derived platelet may required course therapy but just 10% apheresis.Lack facilities, clinicians' are contributing extremely Nigeria.